Effect Of Rilapladib (SB-659032) On Platelet Aggregation

GlaxoSmithKline58 enrolled

Overview

The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

DOUBLE

Enrollment

Conditions

Healthy Subjects Atherosclerosis

Interventions

Rilapladib (SB-659032)DRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with QTc \< 450 msec as measured at screening. Exclusion Criteria: * History of asthma. * Smokers.

Locations (1)

GSK Investigational Site

Randwick, New South Wales, Australia

Outcomes

Primary Outcomes

Collagen EC50 values on Day 35 (or 21 days post last dose) as determine by optical aggregometry.

Time frame: on Day 35 (or 21 days post last dose) as determine by optical aggregometry

Secondary Outcomes

Collagen EC50 values on Day 1 and Day 14 as determined by optical aggregometry Plasma Lp-PLA2 activity Clinical safety data Concentrations of rilapladib and SB-664601.

Time frame: on Day 1 and Day 14 as determined by optical aggregometry

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.